CeNeS Pharmaceuticals (AIM:CEN) (“CeNeS” or “the Company”) the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs1 further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts in the brain would be a useful agent to address profound cognitive deficits in schizophrenia and bipolar disorder. CeNeS has an ongoing discovery programme to develop novel COMT inhibitors.
